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BCL2L12 has been found to be associated with favorable prognosis in breast cancer patients while
correlated with tumorigenesis of glioblastoma and colon cancer. Here, we report that BCL2L12
and its transcript variant BCL2L12A are degraded through ubiquitin-proteasome system (UPS).
Interestingly, the ubiquitinations and degradations of BCL2L12 and BCL2L12A are independent of
the internal lysine residues but the ﬁrst N-terminal residues. In addition, HSP70 was identiﬁed to
interact with BCL2L12 and BCL2L12A and protected them from ubiquitinations and degradations
in mammalian cells. In summary, HSP70 protects BCL2L12 and BCL2L12A from N-terminal ubiquiti-
nation-mediated proteasomal degradation.
Structured summary:
MINT-7026352, MINT-7026366: BCL2L12 (uniprotkb:Q9HB09-1) physically interacts (MI:0218) with
Hsp70 (uniprotkb:P62988) by anti tag coimmunoprecipitation (MI:0007)
MINT-7026290: BCL2L12 (uniprotkb:Q9HB09-1) physically interacts (MI:0218) with ubiquitin (uni-
protkb:P62988) by pull down (MI:0096)
MINT-7026326: Hsp70 (uniprotkb:P08107) physically interacts (MI:0218) with BCL2L12A (uni-
protkb:Q9HB09-2) by anti bait coimmunoprecipitation (MI:0006)
MINT-7026338: BCL2L12 (uniprotkb:Q9HB09-1) physically interacts (MI:0218) with Hsp70 (uni-
protkb:P08107) by anti tag coimmunoprecipitation (MI:0007)
MINT-7026304: BCL2L12A (uniprotkb:Q9HB09-2) physically interacts (MI:0218) with Hsp70 (uni-
protkb:P08107) by anti tag coimmunoprecipitation (MI:0007)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction The ubiquitin-proteasome system (UPS) is involved in selectiveBCL2L12 is a newly identiﬁed member of Bcl2 family. It has two
splicing variants: the classical form of the gene and a truncated
form called BCL2L12A which lacks exon 3. BCL2L12 and BCL2L12A
have been reported to be transcriptionally regulated in HL-60,
MCF-7 and MDA-MB-231 cells in response to several anti-tumor
drugs, including cisplatin, carboplatin and methotrexate [1–3].
However, the post-translational modiﬁcations and regulations of
these proteins have not been studied yet.chemical Societies. Published by E
DH, glyseraldehyde-3-phos-
mide; EGFP, enhanced green
Center, Shanghai Medical
uan Road, Shanghai 200032,
u@shmu.edu.cn (J. Gu).targeting of innumerable cellular proteins for modiﬁcation and
degradation, including oncoproteins and tumor suppressors, tran-
scriptional factors, receptors, cell cycle regulators, and abnormal/
misfolded/mutated proteins [4–6]. Characterized by the initial site
of ubiquitination, there are two sub-pathways of the ubiquitin sys-
tem, the conventional lysine-dependent pathway and the non-con-
ventional N-terminus-dependent pathway. For most substrates, it
is believed that the ﬁrst ubiquitin moiety is conjugated to the e-
NH2 group of an internal lysine residue.
Inducible heat shock protein 70 (HSP70) is one of the most
important HSPs for cell integrity maintenance during normal cellu-
lar growth as well as pathophysiological conditions. HSP70 regu-
lates the ubiquitination and degradation of signaling or
misfolded proteins, such as Smad 1 and IjBa, through binding to
CHIP in the cytosol [7,8]. HSP70 could also protect some proteins,
such as tumor necrosis factor receptor-associated factor 6 (TRAF6),lsevier B.V. All rights reserved.
1410 J. Yang et al. / FEBS Letters 583 (2009) 1409–1414from ubiquitination and degradation through proteasome [9].
However, HSP70 functions in regulating the post-translational
modiﬁcation of nuclear proteins have rarely been studied.
In the present study, we show that BCL2L12 and BCL2L12A are
novel substrates of the UPS that are targeted for degradation via N-
terminal ubiquitination. HSP70 interacts with BCL2L12 and
BCL2L12A and protects them from ubiquitination and degradation
through proteasome.
2. Materials and methods
2.1. Reagents
CHX, Leupeptin, aprotinin and PMSF were purchased from Sig-
ma. MG132 and lactacystin were purchased from Calbiochem. Pro-
tein G-agarose, PVDF Membrane and mouse anti-EGFP antibody
were purchased from Roche. Mouse anti-myc antibody was pur-
chased from Invitrogen. Mouse anti-Ub, mouse anti-HA, mouse
anti-GAPDH, mouse normal IgG antibodies and Hsp70 siRNA were
purchased from Santa Cruz Biotechnology Inc. ECL assay kit was
purchased from Amersham Biosciences.
2.2. Cell culture and cell transfection
HeLa, HEK293T and COS-1 cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% FBS, 100 units/
ml penicillin and 50 lg/ml streptomycin at 37 C in a humidiﬁed
incubator (5% CO2, 95% air). Cell transfections were performed
using Lipofectamine2000 (Invitrogen) according to the manual.
2.3. Plasmids constructions and mutagenesis
BCL2L12 and BCL2L12A were constructed as indicated [10].
BCL2L12 mutants were ampliﬁed using TakaRa MutanBEST muta-
genesis kit.
2.4. In vivo ubiquitination assay
Cells were treated with 50 lM MG132 or 25 lM lactacystin for
6 h prior to harvest. Cells were lysed in 100 ll modiﬁed RIPA buffer
(150 mM NaCl 1% NP-40 0.5% deoxycholate 0.1% SDS, 50 mM Tris–
HCl, pH7.5 1 mM PMSF 10 lg/ml aprotinin 5 mg/ml leupeptin)
with 1% SDS and boiled for 10 min to disrupt protein–protein inter-
action, and then diluted in 900 ll RIPA buffer. The lysates were
sonicated brieﬂy on ice and clariﬁed by centrifugation. The super-
natants were subject to nickel agarose puriﬁcation or immunopre-
cipitation. For Factor Xa cleavage, prior to nickel agarose
puriﬁcation, extracts were treated with 1 lg factor Xa protease
for 16 h at 25 C.
2.5. Half-life assay
HeLa cells were transiently transfected with BCL2L12 or its mu-
tants. 40 h after transfection, cells were treated with 100 lg/ml
CHX as indicated. The cells were harvested and 50 lg of cell lysates
were analyzed with anti-EGFP and anti-GAPDH antibodies. The
protein levels were calculated using Totallab2.01 software and
the values of BCL2L12 were plotted against the values of glyseral-
dehyde-3-phosphate dehydrogenase (GAPDH). BCL2L12/GAPDH
ratio at 0 h was taken as 100%. The assay was repeated indepen-
dently three times.
2.6. Immunoprecipitation
Cells in 100-mm dishes were transfected with 12 lg total plas-
mids. Approximately 36 h after transfection, cells were cultured inmedia containing DMSO or MG132. After another 6 h, the cells
were washed and solubilized with co-immunoprecipitation buffer
(50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1% Nonidet P-40, 5 mM
EDTA, 5 mM EGTA, 15 mM MgCl2, 60 mM b-glycerophosphate,
0.1 mM sodium orthovanadate, 0.1 mM NaF, 0.1 mM benzamide,
10 lg/ml aprotinin, 10 lg/ml leupeptin and 1 mM PMSF). CoIP
was performed as before [11]. Tandem MS analysis of BCL2L12A-
interacting proteins was performed by Institute of Biomedical Sci-
ence of Fudan University.3. Results and discussion
3.1. Lysine-independent degradation of BCL2L12 and BCL2L12A
through ubiquitin-proteasome pathway
We identiﬁed BCL2L12 from a yeast two-hybrid system as a
binding partner of small glutamine-rich TPR-containing protein
(SGT), an apoptotic protein [12]. In order to investigate its biolog-
ical function in mammalian cells, myc-tagged BCL2L12 and
BCL2L12A were transfected into several mammalian cells, includ-
ing HeLa, 293T, MCF-7, MDA-MB-231 and COS-1 cells. However,
the expression levels of BCL2L12 and BCL2L12A were relatively
low in those cells. We suspected this phenomenon might be asso-
ciated with rapid degradations of both proteins in those cells. Two
main organelle compartments responsible for the degradation of
cellular proteins are lysosome and proteasome [13,14]. Thus,
24 h after transfection, 293T cells are treated with NH4Cl
(20 mM), an inhibitor of lysosome [15], and MG132, an inhibitor
of proteasome, respectively. As depicted in Fig. 1B and D, NH4Cl
had no effect on the expression levels of BCL2L12 and BCL2L12A,
whereas MG132 evidently increased BCL2L12 and BCL2L12A levels,
implying that BCL2L12 and BCL2L12A might be degraded through
proteasome pathway. To further conﬁrm the hypothesis, lactacys-
tine, a speciﬁc inhibitor of the 20S proteasome [16], was used and
gave the same result as MG132 (Fig. 1B and D). Studies have indi-
cated that targeting of substrates to the proteasome is usually
accomplished by conjugating of a poly-ubiquitin chain to an inter-
nal lysine [17,18]. Accordingly, we asked whether BCL2L12 and
BCL2L12A are degraded in ubiquitin-dependent manners in mam-
malian cells. 293T cells were co-transfected with a mutant ubiqui-
tin with all of its lysines mutated to arginines [Ub (K0) mutant], in
the presence of which, BCL2L12 and BCL2L12A accumulated in
cells (Fig. 1C and E), suggesting that inhibition of poly-ubiquitin
chain formation does not allow for efﬁcient degradation of
BCL2L12 and BCL2L12A.
Poly-ubiquitin chains are usually formed by conjugation of Ub
moieties to the e-amino group of lysine residues of the substrates
[19]. To further characterize the ubiquitinations of BCL2L12 and
BCL2L12A, we constructed lysineless mutants of BCL2L12 and
BCL2L12A by replacing the lysines with arginines (Fig. 1A and F).
The wild-type proteins and the lysineless mutants were transiently
transfected into HeLa cells. Surprisingly, we observed that lysine-
less mutants were still expressed at low levels similar to those of
the wild-type proteins, and mutant proteins were dramatically
up-regulated by MG132 in the same pattern and extent (Supple-
mentary Fig. 1). As a splice variant of BCL2L12, BCL2L12A shares
exactly the same sequence as BCL2L12 from the ﬁrst amino acid
to the 120th amino acid. The similarities in the expression levels
of BCL2L12 and BCL2L12A and in responses to MG132 allowed us
to suspect that the N-terminal sequence shared by BCL2L12 and
BCL2L12A might be responsible for the degradation. According to
this, BCL2L12(1-120aa) and BCL2L12(1-120aa)-0K (Fig. 1F) were
constructed and the ubiquitination assay was carried out. As
expected, these two mutants expressed at low levels and were
greatly increased by MG132 (Fig. 1G). Ladders of high-mobility
Fig. 1. Lysine independent degradation of BCL2L12A through ubiquitin-proteasome pathway. (A) Schematic representation of BCL2L12 and BCL2L12A. (B and C) BCL2L12
expression levels in response to different treatment. (D and E) BCL2L12A expression levels in response to different treatment. (F) Amino acid sequences of BCL2L12 and
BCL2L12A. Lysines underlined were substituted with arginine. (G) Ubiquitinations of pcDNA3.1-BCL2L12(1-120aa) and pcDNA3.1-BCL2L12(1-120aa)-K/R.
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120aa) and BCL2L12(1-120aa)-0K were clearly detected with a
Ub antibody (Fig. 1G). These results suggested that BCL2L12 and
BCL2L12A are degraded through ubiquitin-proteasome pathway
in vivo and the internal lysine residues are dispensable for the
ubiquitin-conjugation.Fig. 2. Addition of a large N-terminal tag stabilizes BCL2L12(1-120aa). (A) Fluorescent m
120aa)-0K. (B and C) The half-lives of EGFP-tagged BCL2L12(1-120aa) and its mutants.3.2. Addition of a large N-terminal tag stabilize BCL2L12(1-120aa) and
BCL2L12(1-120aa)-0K
Recent ﬁndings indicated that for several proteins, the ﬁrst
ubiquitin moiety is fused linearly to the a-NH2 group of the N-ter-
minal residue and addition of a large tag such as 6 Myc oricroscopic analysis and ubiquitination assay of BCL2L12(1-120aa) and BCL2L12(1-
Fig. 3. BCL2L12(1-120aa) was ubiquitinated at the N-terminus in vivo. (A)
Ubiquitination assay of BCL2L12(1-120aa) and its mutants with a Factor Xa
recognition sequence. (B) Ubiquitination assay of BCL2L12(1-120aa) and its
mutants without a Factor Xa recognition sequence.
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proteins [20–24]. According to these, we supposed that BCL2L12
and BCL2L12A might also be modiﬁed at the N-terminus. In order
to testify this hypothesis, EGFP was added to the N-terminuses of
BCL2L12(1-120aa) and BCL2L12(1-120aa)-0K. Meanwhile, C-Fig. 4. Identiﬁcation of HSP70 as a new binding partner of BCL2L12A. (A and B) SDS–PA
peptides of HSP70 identiﬁed by mass spectrometry (left panel). PM: protein marker. (C,
HSP70 in vivo. ‘‘” indicated a non-speciﬁc band.terminal EGFP tagged constructs were also made to exclude the
impact of EGFP. Fusion of EGFP to the C-terminuses of
BCL2L12(1-120aa) and BCL2L12(1-120aa)-0K had little inﬂuence
on the protein expressions, while fusion of EGFP to the N-terminus
of these two proteins dramatically increased their levels (Fig. 2A).
Moreover, MG132 signiﬁcantly elevated the protein level of
BCL2L12(1-120aa)-EGFP regardless of the internal lysines, similar
to that of BCL2L12(1-120aa)-myc (Fig. 2A).
We then measured the half-lives by cycloheximide (CHX) chase
experiments. BCL2L12(1-120aa)-EGFP and BCL2L12(1-120aa)-
0K-EGFP were degraded rapidly with half-lives of both
approximate 90 min (Fig. 2B and C), while fusion of EGFP to the
N-terminus of BCL2L12(1-120aa) and BCL2L12(1-120aa)-0K
dramatically stabilized them, with half-lives of both approximate
9 h.
3.3. BCL2L12(1-120aa) is ubiquitinated at the N-terminus in vivo
Since BCL2L12(1-120aa) ubiquitinylation does not require the
presence of lysine residues and addition of a large N-terminal tag
stabilize BCL2L12(1-120aa), we sought to identify that the poly-
ubiquitin chains are directly conjugated to the free NH2 of the ﬁrst
amino acid of BCL2L12(1-120aa) and BCL2L12(1-120aa)-0K. We
generated constructs of wild-type BCL2L12(1-120aa) and the
BCL2L12(1-120aa)-0K mutant that after the ﬁrst methionine con-
tain an HA tag (which does not contain any lysine: Tyr-Pro-Tyr-
Asp-Val-Pro-Asp-Tyr-Ala) followed by a factor Xa protease cleav-
age site (Ile-Glu-Gly-Arg) as previously described [25]. These con-
structs or pcDNA3.1 were transfected into 293T cells, respectively.
The cell lysates from these transfected cells were treated with or
without factor Xa as indicated above. Then, HA tag was efﬁciently
removed as shown by delayed gel-migrations (Fig. 3A, lower pa-
nel). Without factor Xa treatment, BCL2L12(1-120aa) and
BCL2L12(1-120aa)-0K showed clear ubiquitin-conjugation bands,
which were abolished in those incubated with factor Xa (Fig. 3A,
upper panel). To eliminate the possibility that factor Xa might haveGE and mass spectrometry analysis of BCL2L12A-interacting proteins. Listed were
D and E) Co-immunoprecipitation of BCL2L12A, BCL2L12 or BCL2L12(1-120aa) with
Fig. 5. HSP70 inhibited the ubiquitination and degradation of BCL2L12(1-120aa). (A and B) The effect of HSP70 on BCL2L12(1-120aa) half-life. (C) Ectopic expression of HSP70
inhibited the ubiquitination and degradation of BCL2L12(1-120aa). (D) Knock-down of endogenous HSP70 with speciﬁc siRNA promoted the degradation of BCL2L12(1-
120aa).
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plasmids was made as indicated in Fig. 3B, which lacked the factor
Xa cleavage sequence. The same procedure was carried out as in
Fig. 3A. However, factor Xa had no effect on the migration rates
and ubiquitination states of BCL2L12(1-120aa) and BCL2L12(1-
120aa)-0K without factor Xa recognition sequence (Fig. 3B). These
results indicate that BCL2L12 and BCL2L12A are ubiquitinated on
their N-terminal residues.3.4. Identiﬁcation of HSP70 as a new binding partner of BCL2L12 and
BCL2L12A
To further explore the factors responsible for the degradation of
BCL2L12A, we expressed EGFP and EGFP-tagged BCL2L12A in 293T
cells. The proteins from 12  100 mm dishes (6 dishes of approxi-
mate 1.8  106 cells each) were precipitated with anti-EGFP anti-
body, and subjected to SDS–PAGE and Commassie Blue G-250
staining (Fig. 4A). The differentially associated proteins were cut
out and analyzed by mass spectrometry. Liquid chromatography
tandem mass spectrometry revealed that HSP70 is a BCL2L12A-
interacting protein (Fig. 4A and B), which was conﬁrmed by co-
immunoprecipitation experiment (Fig. 4C). We also found that
BCL2L12 could interact with HSP70 in vivo (Fig. 4D). The sequence
responsible for this interaction is within the N-terminal 120 amino
acids that are possessed by both proteins (Fig. 4E).3.5. HSP70. inhibits the ubiquitination and degradation of BCL2L12(1-
120aa)
We then investigated whether HSP70 could inﬂuence the ubiq-
uitination and degradation of BCL2L12(1-120aa). pcDNA3.1-
BCL2L12(1-120aa) was co-transfected with pcDNA3.1 or HSP70
into 293T cells. The half-lives of BCL2L12(1-120aa) were measured
using CHX-chase assay (Fig. 5A). Normally, the half-life of
BCL2L12(1-120aa)-myc was about 60 min in 293T cells, which
was prolonged to about 3 h when HSP70 was over-expressed
(Fig. 5B). Next, we examined the ubiquitination of BCL2L12(1-120aa), which was found to be inhibited by the ectopic expression
of HSP70 (Fig. 5C). On the contrary, knock-down of the endogenous
HSP70 with speciﬁc siRNA led to an evidently decrease of
BCL2L12(1-120aa) in the protein level (Fig. 5D).
Taken together, we demonstrated in this study that BCL2L12
and BCL2L12A are regulated by N-terminal ubiquitination medi-
ated proteasomal degradation, which could be protected by
HSP70. This new ﬁnding might help us to learn more about the reg-
ulation of N-terminal ubiquitination.
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